Company intelligence / Profile preview

Regentys

Florida, United States

Ownership: Private
Development stage: Other

Overview

Regentys has completed multiple preclinical studies with ECMH showing restoration of cell barrier function, promotion of rapid tissue regeneration, reduction in clinical symptoms, and reversal of inflammation and ulceration in GI models. The company planned to start a pilot study for ulcerative colitis, with future studies and applications possible in Crohn’s disease and rectal mucositis. The product is to be regulated as a device (FDA 510K de novo pathway)[1][3].

Therapeutic areas: Gastroenterology
Modalities: Hydrogel-based drug delivery therapyDeviceBiologic
Industry: Therapeutic Medical Devices

Partnerships

Generex Biotechnology

Beyond the preview

Go deeper on Regentys.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Regentys.

Explore the full profile